Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Pasil; Pasil Injection; Pazucross; Pazufloxacin Injection; Pazufloxacin mesilate; T 3761; T 3762

Latest Information Update: 29 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Toyama Chemical
  • Developer FUJIFILM Toyama Chemical; Mitsubishi Tanabe Pharma Corporation
  • Class Anti-infectives; Antibacterials; Fluoroquinolones; Oxazines; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Bacterial infections; Legionnaires' disease; Pneumococcal infections; Sepsis

Most Recent Events

  • 23 Jul 2010 Launched for Pneumococcal infections in Japan (IV)
  • 23 Jul 2010 Launched for Sepsis in Japan (IV)
  • 23 Jul 2010 Registered for Pneumococcal infections in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top